TY - JOUR
T1 - The rise of allogeneic Natural killer cells as a platform for cancer immunotherapy
T2 - Recent innovations and future developments
AU - Veluchamy, John P.
AU - Kok, Nina
AU - van der Vliet, Hans J.
AU - Verheul, Henk M.W.
AU - de Gruijl, Tanja D.
AU - Spanholtz, Jan
PY - 2017/5/31
Y1 - 2017/5/31
N2 - Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
AB - Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
KW - Adoptive natural killer cell therapy
KW - Allogeneic natural killer cells
KW - Autologous natural killer cells
KW - Hematopoietic stem cell transplantation
KW - Natural killer cell biotech companies
KW - Natural killer cell combinatorial studies
UR - http://www.scopus.com/inward/record.url?scp=85020039545&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fimmu.2017.00631
DO - https://doi.org/10.3389/fimmu.2017.00631
M3 - Review article
C2 - 28620386
SN - 1664-3224
VL - 8
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - MAY
M1 - 631
ER -